Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Chakraborty R et al. Blood Cancer J. 2016 Dec 16;6(12):e512. doi: 10.1038/bcj.2016.117. A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Botta C et al. Blood Cancer J. 2016 Dec 16;6(12):e511. doi: 10.1038/bcj.2016.118. 68Ga-PSMA PET/CT Imaging in Multiple Myeloma. Sasikumar A et…Details
No publications related to this topic were published this month.
Are neurological complications of monoclonal gammopathy of undetermined significance underestimated
Steiner N et al. Oncotarget. 2016 Dec 10. doi: 10.18632/oncotarget.13861. [Epub ahead of print].
Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case.
González-Calle V et al. Clin Case Rep. 2016 Oct 11;4(12):1096-1100. eCollection 2016.
Proteomic profiling in plasma cell disorders: a feasibility study. Mailankody S et al. Leuk Lymphoma. 2016 Dec 2:1-3. [Epub ahead of print]. Tumor-associated macrophage-mediated survival of myeloma cells through STAT3 activation. De Beule N et al. J Pathol. 2016 Dec 15. doi: 10.1002/path.4860. [Epub ahead of print]. Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. Dao K et…Details
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. Berenson A et al. Ann Hematol. 2016 Dec 8. [Epub ahead of print]. Practical Considerations in Managing Relapsed Multiple Myeloma. Agarwal A et al. Clin Lymphoma Myeloma Leuk. 2016 Nov 23. pii: S2152-2650(16)30873-4. doi: 10.1016/j.clml.2016.11.010. [Epub ahead of print]. Effects of Stress Appraisal on the Quality of Life of Adult Patients with Multiple Myeloma and Their Primary Family…Details
Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study. Hansen PB et al. Support Care Cancer. 2016 Dec 13. [Epub ahead of print]. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Di Nisio M et al. Cochrane Database Syst Rev. 2016 Dec…Details
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Jones JR et al. Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114. Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. Hinduja A et al. PLoS One. 2016 Nov 30;11(11):e0166627. doi: 10.1371/journal.pone.0166627. eCollection 2016. Bullous skin lesions in a patient…Details
Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Skerget M et al. Radiol Oncol. 2016 May 12;50(4):402-408. eCollection 2016. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma – a phase II…Details
Results from the national Myeloma XI trial have shown a higher incidence of second primary malignancies (SPM) in patients receiving Revlimid (lenalidomide) maintenance treatment compared to those who did not, in line with other previous reported trials. Published in the Blood Cancer Journal analysis of the data showed that, although the overall incidence of SPM was…Details
Celgene, the Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences (UAMS) have announced that they have partnered to create the Myeloma Genome Project to compile high quality genetic and clinical data to improve diagnosis, prognosis and treatment for myeloma patients. The aim is to develop a strategy for classifying myeloma into subgroups…Details